NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough to prevent deficiency, the optimal daily intake is probably 200 mg, according to results of a new NIH-sponsored study. The current Recommended Dietary Allowance (RDA) is 60 mg.

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough toprevent deficiency, the optimal daily intake is probably 200 mg,according to results of a new NIH-sponsored study. The currentRecommended Dietary Allowance (RDA) is 60 mg.

In this study, vitamin C was given in various amounts to sevenhealthy young male volunteers who lived in a hospital ward forthe duration of the study so that intake could be strictly controlled.The NIH researchers, led by Dr. Mark Levine, found that the 200mg level was best absorbed by the body; absorption levels fellas the dose was raised above 200 mg.

Daily doses higher than 400 mg offer no additional value, Dr.Levine said, since, at that level, a large amount of the doseis excreted from the body. The research also suggests that veryhigh doses could be dangerous: At 1,000 mg/day, the urine wasfound to contain oxalate, a breakdown product of the vitamin thatcould lead to kidney stone formation in some people.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content